• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » How Essential Is Antidepressant Continuation?

How Essential Is Antidepressant Continuation?

June 1, 2022
Michael Posternak, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue

Michael Posternak, MD. Dr. Posternak has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

REVIEW OF: Lewis G et al, N Eng J Med 2021;385(14):1257–1267

TYPE OF STUDY: Randomized controlled trial

Most of us have been taught that long-term antidepressant therapy is crucial for patients who have had three or more episodes of depression. This idea is based on trials in which patients in remission were randomly assigned to medication continuation vs placebo. Those switched to placebo had a higher rate of relapse, especially if they’d had three prior episodes of depression.

However, these studies have a number of flaws that may bias the results. Generally, these patients were in remission for only a short amount of time—typically from three to eight months. Second, antidepressant discontinuation was typically done rapidly, making it hard to tell whether patients actually relapsed or were suffering from withdrawal symptoms. Third, the switch to placebo took place at a fixed time instead of when patients felt ready to come off their antidepressant. That leaves open the question: Can patients who have been in sustained remission from depression and feel ready to come off medication safely discontinue antidepressants?

In this study, researchers recruited 478 adult patients from 150 general practices across England, all of whom had a history of at least two prior depressive episodes, were currently in remission, had been taking their antidepressant for at least nine months, and felt well enough to consider stopping their medication. Only antidepressants that are commonly prescribed and known to have low rates of withdrawal were included: citalopram, sertraline, fluoxetine, and mirtazapine. Consenting patients were randomized in a double-blind manner to either remain on their antidepressant or have it slowly replaced with a placebo over two months (fluoxetine was tapered over only one month due to its long half-life). Patients were then followed every three months for one year to ascertain relapse rates.

In total, 92 of 238 patients (39%) in the maintenance group relapsed compared to 135 of 240 (56%) in the discontinuation group over the course of 52 weeks (HR 2.06; p < .0001). Differences in rates of depression, anxiety, and quality of life all emerged within 12 weeks and persisted throughout the trial. Of the patients who stopped their trial medication, 20% of the maintenance group and 39% of the discontinuation group elected to resume antidepressant medication.

One potential limitation of the study is that reported rates of medication withdrawal symptoms were higher in the discontinuation group (3.1) than the maintenance group (1.9; 95% CI 1.5–2.3). Although this could represent an unmasking of depressive symptoms, it also suggests that despite the slow taper, physiological withdrawal cannot be ruled out as a contributing factor.

CARLAT TAKE
This landmark study puts the risks of antidepressant discontinuation in perspective. On the one hand, staying on the medication lowers the relapse risk by 17% over the course of a year. On the other hand, 44% of discontinuation patients did taper off their antidepressant without relapsing. Those figures challenge the black-and-white recommendation to remain on an antidepressant indefinitely after more than two episodes and move the question into the realm of collaborative decision-making between clinician and patient.

KEYWORDS antidepressant discontinuation antidepressants depression
    Michael Posternak, MD

    Moderate Alcohol Use Associated With Reduced Risk of Dementia

    More from this author
    www.thecarlatreport.com
    Issue Date: June 1, 2022
    SUBSCRIBE NOW
    Table Of Contents
    Quetiapine Reconsidered
    Psychosis During Depression
    Can TMS Turn on the Switch?
    Uncommon Tips: Which Is Better—Citalopram or Escitalopram?
    Benzodiazepines: A Reevaluation of Their Benefits and Dangers
    How Essential Is Antidepressant Continuation?
    Hypothyroidism and Depression: Just How Related Are They?
    Topiramate Improves Weight in Schizophrenia in South Asians
    CME Post-Test - Psychotic Depression, TCPR, June/July 2022
    DOWNLOAD NOW
    Featured Book
    • HospPsychiatry_Spiral_Binding_Sm.png

      Hospital Psychiatry Fact Book, First Edition (2025) - Spiral Bound

      This comprehensive guide is designed to be a valuable resource for professionals working in...
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2603816031.jpg
      General Psychiatry

      A Scam for Every Woman, Child, and Man: Part 2

      1 in 3 Americans were victims of online scams in the past year. Even when you know your patient is being scammed, it is hard to pull them out. We speak with Cathy Wilson about...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.